Tactile Therapeutics

Trimtech Therapeutics

This biotechnology company develops small molecule drugs that target and degrade toxic protein aggregates to treat neurodegenerative and inflammatory diseases.

Sibylla Biotech

This company develops small molecule protein degraders for pharmaceutical partners and clinical research to treat oncological and neurodegenerative diseases.

Plexium

This company develops targeted protein degradation therapeutics and discovery platforms for patients with cancer and neurodegenerative diseases.

Kesmalea Therapeutics

This drug discovery company develops oral, central nervous system penetrant protein degraders to treat oncology and neurological diseases.

Enodia

This company develops small-molecule therapies that degrade disease-causing proteins at the point of synthesis for patients with cancer and inflammatory diseases.

Enodia Therapeutics

This biotechnology company develops small-molecule therapies for targeted protein degradation to treat inflammatory, autoimmune and oncological diseases in patients.

Ligature Therapeutics

This biotech company develops protein degrader therapeutics using a fragment-based discovery platform to treat intractable diseases for patients with cancer.

ProteoValent Therapeutics

This company develops targeted protein degrader therapies for cancer and haematology patients.